Company: BIAF
Filing Date: 2025-05-27
Form Type: 424B5
Source: 0001641172-25-012410
Chunk: 0

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-27
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-275608

PROSPECTUS SUPPLEMENT

(To Prospectus dated November 27, 2023)

<div align='center'>Up to $5,801,000 Shares of Common Stock</div>

We have entered into an At-the-Market Issuance Sales Agreement, dated May 22, 2025 (the “Sales Agreement”), with WallachBeth Capital LLC (“WallachBeth” or the “Sales Agent”) relating to the sale of shares of our common stock, par value $0.007 per share (the “common stock”), having an aggregate offering price of up to $5,801,000 from time to time through or to WallachBeth, acting as sales agent or principal, pursuant to this prospectus supplement and the accompanying base prospectus.

Sales of shares of our common stock, if any, under this prospectus supplement will be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on or through the Nasdaq Stock Market (“Nasdaq”) or any other existing trading market in the United States for our common stock, sales made to or through a market maker other than on an exchange or otherwise, directly to WallachBeth as principal, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or in any other method permitted by law. WallachBeth is not required to sell any specific number or dollar amount of shares but will use its commercially reasonable efforts to sell on our behalf all of the shares of our common stock requested to be sold by us, consistent with its normal trading and sales practices, subject to the terms of the Sales Agreement on mutually agreed terms between WallachBeth and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

As sales agent, WallachBeth will be entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold under the Sales Agreement. In connection with the sale of our common stock on our behalf, WallachBeth will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of WallachBeth will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution